'Ozempic 2.0' is on the way and could completely change weight loss drugs

Eli Lilly is advancing an oral GLP candidate, orforglipron, with trials showing average weight reductions of 10.5% (22.9 lbs) versus 2.2% (5.1 lbs) for placebo and 8.2% versus 5.3% for oral semaglutide across all participants; at the highest dose it produced 9.2% weight loss versus 5.3% for semaglutide. The drugmaker is pursuing global regulatory submissions as it vies with Novo Nordisk in the fast-growing anti-obesity market, a potential demand driver for patients who prefer pills to injections, though ultimate market impact depends on FDA and other approvals.

Analysis

Market structure: Lilly (LLY) stands to gain market share and pricing power if orforglipron gains FDA approval and global uptake by 2026; estimate peak addressable obesity/T2D oral market could be $10–30bn annually, putting downward pressure on injectable growth for Novo Nordisk (NVO) by 10–25% over 3–5 years. Downstream winners include contract manufacturers of small-molecule oral APIs and retail pharmacies; losers include needle-delivery device suppliers and premium-priced injectable incumbents without oral pipelines.

Risk assessment: Key tail risks are FDA safety signals, patent-litigation delays, or manufacturing scale failures — any of which could push approvals beyond 2026 and halve near-term upside. Near-term (days–weeks) volatility will hinge on regulatory filings and analyst revisions; medium term (6–18 months) depends on payer coverage decisions and 2026 launch sequencing; long-term (2–5 years) depends on real-world adherence and margin normalization.

Trade implications: Implement a relative-value pair: overweight LLY (2–3% net exposure) and underweight NVO (1–2%) — capitalizing on orforglipron data advantage; finance with NVO Jan 2026/2027 LEAP puts sized to hedge 40–60% of notional. Use options: buy LLY Jan 2027 LEAP 30–40% OTM calls and sell nearer-term calls to fund cost; take profits at +25–35% or on positive FDA submission within 6–12 months.

Contrarian: Consensus underestimates payer resistance — insurers may demand outcomes contracts which will cap list-price realization, and oral manufacturing scale and GI tolerability could cap adoption to <40% of injectable demand. Historically, oral-class shifts take 3–7 years (e.g., oral anticoagulants); a rapid 2026 market share shift is possible but not guaranteed, so size positions with 12–24 month optionality, not full conviction.

Key Decisions for Investors

• Establish a 2–3% long position in Eli Lilly (LLY) equity ahead of regulatory submissions; target entry on any pullback of 3–7%, trim half at +25% and the remainder at +40% or upon FDA approval for orforglipron.
• Initiate a 1–2% short position in Novo Nordisk (NVO) to express risk of share loss to oral competitors; consider financing via buying Jan 2027 put spreads (e.g., 30–40% OTM / 50% width) to limit capital and define downside.
• Buy LLY Jan 2027 LEAP calls (30–40% OTM) sized to ~0.5–1% notional of portfolio and sell 6–9 month covered calls to reduce cost; exit or roll if FDA submission occurs within 6–12 months or volatility compresses by >30%.
• Reduce exposure to injectable device suppliers and mid-cap device names by 1–2% (reallocate to pharma/CMO exposure); rotate into contract manufacturers of oral APIs and retail pharmacy plays (e.g., marginally increase exposure to CVS/CVS Health or WBA) if payer contracts trend favorable in 6–12 months.
• Monitor three catalysts over next 90–180 days — (1) FDA briefing calendars, (2) payer/NHS statements on oral coverage, (3) Lilly/Novo trial/regulatory timelines — and cut positions by 50% if adverse regulatory feedback or safety signals emerge.